ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1867

YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis

Kazuteru Noguchi1, Tetsuya Furukawa2, Takahiro Yoshikawa1, Mai Morimoto1, Teppei Hashimoto2, Naoto Azuma3 and Kiyoshi Matsui2, 1Hyogo Medical University, Nishinomiya, Japan, 2Hyogo college of Medicine, Nishinomiya, Japan, 3Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

Meeting: ACR Convergence 2022

Keywords: Myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: YKL-40 is a chitinase-like protein that is associated with interstitial lung disease in patients with polymyositis (PM)/dermatomyositis (DM) but not with myositis. Myositis pathogenesis is complex, and atypical myositis is clinically classified as PM/DM albeit with reduced muscle weakness. Here, we investigated whether YKL-40 is associated with PM/DM and assessed its role in PM/DM pathogenesis.

Methods: Thirty-five patients diagnosed with PM/DM based on Bohn and Peter’s classification criteria were retrospectively enrolled and evaluated at Hyogo Medical University Hospital from 2006 to 2020 and the results were compared with those of 26 healthy controls (HC). Patients satisfied the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM). Serum YKL-40 levels were measured by enzyme-linked immunosorbent assay (ELISA) and age-corrected to YKL-40 percentile values. The correlation between age corrected YKL-40 percentile and serum markers [creatine kinase (CK), C-reactive protein (CRP), and lactic dehydrogenase (LDH)] was determined using the Mann-Whitney U test. Muscle biopsies obtained from two PM and two DM patients were subjected to immunohistochemistry and immunofluorescence staining using anti-YKL-40 and anti-CD68 antibodies to identify inflammatory cells expressing YKL-40.

Results: The mean age, sex ratio, number of patients, symptoms, clinical data, and treatment are shown in TABLE 1. Age-corrected serum YKL-40 values were significantly increased in patients with PM/DM compared to the HC but significantly decreased before and after treatment. Serum YKL-40 levels weakly correlated with CRP but not with CK or LDH. Immunohistochemical analysis showed infiltration of YKL-40-positive inflammatory cells in the endomysium and perimysium of the muscle sheath. Immunofluorescence staining revealed CD68 expression in YKL-40-positive inflammatory cells, suggesting that these cells were macrophages.

Conclusion: We believe that the trend of serum YKL-40 levels in PM/DM patients can reflect myositis. Serum CK and LDH levels indicate muscle destruction as they are derived from muscles. Serum YKL-40 levels did not correlate with serum CK and LDH levels, possibly due to the inclusion of cases with mild muscle destruction. Thus, YKL-40 may be used to evaluate myositis cases with mild muscle damage. CD8+ and CD4+ T cells are believed to play predominant roles in muscle destruction in PM and DM, respectively. However, YKL-40-positive macrophages observed in both diseases suggest that cells other than CD8+ and CD4+ T cells may cause inflammation. This provides new insights to understand pathophysiological mechanisms of atypical myositis.

Supporting image 1

Statistical analysis was performed using the Mann–Whitney U test*¹, and Fisher’s exact test*² (JMP® 14, SAS Institute Inc., Cary, NC, USA). Statistical significance was denoted by p < 0.05 for all tests. All data were expressed as the mean ± SE.


Disclosures: K. Noguchi, None; T. Furukawa, None; T. Yoshikawa, None; M. Morimoto, None; T. Hashimoto, None; N. Azuma, None; K. Matsui, None.

To cite this abstract in AMA style:

Noguchi K, Furukawa T, Yoshikawa T, Morimoto M, Hashimoto T, Azuma N, Matsui K. YKL-40-mediated Inflammatory Pathogenesis Common to Polymyositis / Dermatomyositis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/ykl-40-mediated-inflammatory-pathogenesis-common-to-polymyositis-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ykl-40-mediated-inflammatory-pathogenesis-common-to-polymyositis-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology